The standard categorical system for assessing attribution of toxicity to study drug(s) in phase I trials is cumbersome and uninformative. Although a binary system ("related" vs. "unrelated") would be sufficient to define maximum tolerated dose (MTD), a probability estimation would better support dose selection for randomized dose-ranging phase II trials. Clin Cancer Res; 22(3); 527–9. ©2015 AACR.
See related article by Eaton et al., p. 553
from Cancer via ola Kala on Inoreader http://ift.tt/1P7YN0v
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου